Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2023-08-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于向激励对象授予2022年限制性股票激励计划预留部分权益的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the granting of restricted stock under a 2022 restricted stock incentive plan. It details the approval process, conditions for granting, specific grant details, performance and personal assessment criteria, and legal opinions. The content focuses on the company's equity incentive plan and the allocation of shares to management and key personnel. It is not a financial report, earnings release, or regulatory filing about financial results. Instead, it is a formal announcement about a capital/incentive stock grant event, which fits best under Capital/Financing Update (CAP) as it relates to changes in capital structure through share grants to employees. The document length is sufficient and contains detailed substantive information about the stock incentive plan grant, not just a brief notice or certification, so it is not RPA or RNS.
2023-08-29 Chinese
益丰药房关于2023年半年度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's 2023 half-year main operating data, including key accounting data, business segment revenue, store expansion, and other operational metrics. It contains actual financial figures for the first half of 2023 (January to June), such as revenue, net profit, cash flow, and assets, as well as detailed operational data like store counts and regional distribution. The document is about 3015 characters long, which is relatively short but contains substantive financial and operational data rather than just a notice or link to a report. The content aligns with a comprehensive interim or quarterly report rather than a brief earnings release or a simple announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. H1 2023
2023-08-29 Chinese
前次募集资金使用情况鉴证报告（截至2023年6月30日）
Capital/Financing Update Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Use Verification Report." It contains detailed information about the use of previously raised funds, including amounts raised, usage, changes in usage, investment projects, and financial data related to these projects. The document references regulatory guidelines from the China Securities Regulatory Commission and includes an auditor's verification report. It is a comprehensive report on the use of funds raised in prior financing activities, including convertible bonds and share issuance. This type of document aligns with the category of Capital/Financing Update (CAP), as it provides updates on the use of capital raised and related financing activities rather than being a full annual or interim financial report or an audit report alone. The document length is substantial (15,000 characters), and it contains substantive financial and operational data related to fundraising usage, not just an announcement or certification. Therefore, the appropriate classification is CAP (Capital/Financing Update).
2023-08-29 Chinese
益丰药房关于为子公司申请银行授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding the provision of guarantees for bank credit applications by its subsidiaries. It details the guarantee amounts, the subsidiaries involved, their financial status, and the board's approval of the guarantee. The document is a formal disclosure about financing support activities (guarantees) related to the company's capital structure and credit facilities. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is a specific update on financing-related activities, specifically guarantees for bank credit, which fits the Capital/Financing Update category (CAP). The document length is 3392 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2023-08-29 Chinese
益丰药房关于2022年限制性股票激励计划预留授予激励对象名单（预留授予日）的更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding the 2022 restricted stock incentive plan reserved grant list for certain management and core personnel. It includes detailed tables of stock allocations and names of individuals affected. The document is relatively short (2685 characters) and focuses on correcting previously disclosed information about stock incentives. It does not contain financial statements, earnings data, or detailed management discussion. It is not a full report but an announcement correcting prior disclosures related to stock incentives for management. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement correcting prior disclosures and does not fit other categories like Remuneration Information or Share Issue/Capital Change since it is a correction notice rather than a primary report or initial announcement of stock issuance.
2023-08-29 Chinese
益丰药房2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report." It covers the period from January 1, 2023 to June 30, 2023, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, and other financial indicators, as well as management discussion and analysis, company overview, business operations, and risk disclosures. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial data. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a certification, but the full report itself. Therefore, the correct classification is IR with high confidence. H1 2023
2023-08-29 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.